Wooree Bio우리바이오
082850 · KOSDAQ · ₩082850 · 우리바이오
Valuation model · Discounted cash flow (DCF)
We use a 5-year discounted cash flow: the value of the cash the business is expected to produce, in today's money.
Fair value per share
₩4,612
vs the current price (₩4,260)
- Enterprise value
- ₩102B
- Equity value
- ₩45B
- WACC
- 7.8%
Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal. This is not financial advice.
Bear / Base / Bull
- Bear
- —
- Base
- ₩4,612
- +8.3%
- Bull
- ₩39,431
- +825.6%
Bear: revenue growth 3 points lower every year, EBIT margin 2 points lower, WACC 1 point higher. Bull: the opposite.
Assumptions
Sign in to change the assumptions and see the results update. Sign in
Cycle options
Margin path
Every year uses the cycle-average margin (1.5%).
Revenue growth
- -8.3%
How much sales grow that year, compared with the year before.
Default: the last 3 years' revenue growth (-8.3% a year, annual reports), fading to 3% by year 5.
- -5.5%
How much sales grow that year, compared with the year before.
Default: the last 3 years' revenue growth (-8.3% a year, annual reports), fading to 3% by year 5.
- -2.7%
How much sales grow that year, compared with the year before.
Default: the last 3 years' revenue growth (-8.3% a year, annual reports), fading to 3% by year 5.
- 0.2%
How much sales grow that year, compared with the year before.
Default: the last 3 years' revenue growth (-8.3% a year, annual reports), fading to 3% by year 5.
- 3%
How much sales grow that year, compared with the year before.
Default: the last 3 years' revenue growth (-8.3% a year, annual reports), fading to 3% by year 5.
Business
- 1.5%
Operating profit as a share of revenue.
Default: through-the-cycle average of the last 12 months and the last 5 annual reports' operating margins.
- 27.5%
Share of operating profit paid as corporate tax.
Default: Korea's top corporate tax rate (25%) plus 10% local income tax.
- 2.6%
The non-cash cost of wearing out equipment, added back to cash flow (% of revenue).
Default: not in the statements, so 80% of capital spending (most spending replaces equipment that wears out).
- 3.3%
Money spent on factories, equipment, software and other long-term assets (% of revenue).
Default: average of the last 3 annual reports (cash flow statements; equipment and intangibles).
- 9.4%
Stock and unpaid customer bills, less unpaid supplier bills, as a % of revenue. Each year's extra revenue ties up this much more cash.
Default: working capital (current assets less cash and deposits, minus current liabilities other than borrowings) as a share of revenue, averaged over the last 3 years.
Discount rate
- 2%
How fast cash flows keep growing every year after year 5.
Default: about Korea's long-run inflation plus real growth.
- 4.03%
Yield on Korea's 10-year government bond: the return with almost no risk.
Default: Korea Treasury Bond 10-year yield on 2026-10-27.
- 0.8
How much the share moves when the market moves: 1 means just like the market.
Default: 105 weeks of weekly returns against KOSPI (official index); raw beta 0.71, adjusted toward 1 and kept between 0.6 and 2.0.
- 5.5%
The extra return investors want for owning shares instead of bonds.
Default: a typical premium for Korean shares.
- 5.53%
The interest rate the company would pay to borrow.
Default: the 10-year yield plus a 1.5% credit spread.
Starting point
- Revenue (TTM to H1 2026)
- ₩1.1T
- Net debt (borrowings and leases − cash and deposits)
- ₩7.4B
- + Stakes and investments
- ₩135M
- Associates, long-term financial assets and deposits (book value)
- − Minority interests
- ₩50B
- Shares
- 9,691,315
- Share price
- ₩4,260
- Market cap
- ₩41B
TTM = trailing 12 months: the last four reported quarters added together. "TTM to H1 2026" is the 12 months up to the latest quarterly or half-year report (H1 = to the end of June). Year 1 grows from there.
Past years and projection
Grey columns are reported results from the annual reports (after-tax EBIT at the model's tax rate), so you can check the growth and margin assumptions against the past. Years 1–5 are the model.
| FY2023 | FY2024 | FY2025 | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₩1.3T | ₩1.2T | ₩1T | ₩1T | ₩953B | ₩928B | ₩930B | ₩957B |
| Growth | −6.7% | −2.1% | −15.6% | −8.3% | −5.5% | −2.7% | 0.2% | 3.0% |
| EBIT | ₩26B | ₩15B | ₩952M | ₩15B | ₩14B | ₩14B | ₩14B | ₩14B |
| EBIT margin | 2.1% | 1.2% | 0.1% | 1.5% | 1.5% | 1.5% | 1.5% | 1.5% |
| After-tax EBIT | ₩19B | ₩11B | ₩691M | ₩11B | ₩10B | ₩10B | ₩10B | ₩10B |
| + Depreciation | — | — | — | ₩26B | ₩25B | ₩24B | ₩24B | ₩25B |
| − Capital spending | ₩11B | ₩84B | ₩22B | ₩33B | ₩31B | ₩31B | ₩31B | ₩32B |
| − Working capital | ₩20B | −₩25B | −₩29B | −₩8.6B | −₩5.2B | −₩2.4B | ₩174M | ₩2.6B |
| Free cash flow | — | — | — | ₩12B | ₩8.9B | ₩6B | ₩3.4B | ₩1.1B |
| Discount factor | — | — | — | 0.928 | 0.861 | 0.799 | 0.742 | 0.688 |
| Present value | — | — | — | ₩12B | ₩7.7B | ₩4.8B | ₩2.5B | ₩749M |
Terminal value ₩108B, worth ₩75B today: 73% of enterprise value. It assumes spending settles at 110% of depreciation once growth slows to the terminal rate.
Cross-check: what the market has paid before
For cyclical businesses, analysts check a DCF against the multiples the stock has traded at through past cycles. Price / book is the usual anchor for them: P/E looks highest at the bottom of a cycle, when earnings are smallest, and lowest at the top. The price each band would give today:
| Low | Typical | High | |
|---|---|---|---|
| Price / book (book value ₩22,010 a share)Now 0.19× | ₩9,4180.43× | ₩14,8530.67× | ₩26,4871.20× |
| Price / earnings (last 12 months: ₩361 a share)Now 11.8× | ₩1,7784.93× | ₩3,5439.82× | ₩6,25317.3× |
Low, typical and high are the 10th percentile, middle and 90th percentile of month-end multiples since 2021, each against the latest report out by then, per share at today's share count; loss years and P/E above 100 are left out. Run-rate earnings are one quarter × 4, not a forecast. Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal.
Sensitivity
Fair value per share as two inputs change; the middle is the current case.
| WACC ↓ · Terminal growth → | 1.0% | 1.5% | 2.0% | 2.5% | 3.0% |
|---|---|---|---|---|---|
| 6.8% | ₩6,128 | ₩6,402 | ₩6,726 | ₩7,119 | ₩7,607 |
| 7.3% | ₩5,175 | ₩5,357 | ₩5,568 | ₩5,817 | ₩6,116 |
| 7.8% | ₩4,364 | ₩4,481 | ₩4,612 | ₩4,762 | ₩4,937 |
| 8.3% | ₩3,666 | ₩3,735 | ₩3,809 | ₩3,891 | ₩3,983 |
| 8.8% | ₩3,060 | ₩3,093 | ₩3,126 | ₩3,160 | ₩3,194 |
Now (TTM)
- Market cap
- ₩41B
- Enterprise value
- ₩49B
- P/E
- 11.8×
- P/B
- 0.2×
- P/S
- 0.0×
- EV/EBITDA
- —
- Dividend yield
- 2.3%
Over time (at each year end)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Price | ₩10,175 | ₩13,200 | ₩16,525 | ₩15,000 | ₩22,300 |
| Market cap | ₩99B | ₩128B | ₩160B | ₩145B | ₩216B |
| P/E | — | 27.0× | 10.3× | 6.7× | 6.5× |
| P/B | 0.5× | 0.6× | 0.8× | 0.8× | 1.4× |
| P/S | 0.1× | 0.1× | 0.1× | 0.1× | 0.1× |
| EV/EBITDA | — | — | — | — | — |
| Dividend yield | 1.0% | — | — | — | — |
Versus similar companies
| Company | P/E | P/B | P/S | EV/EBITDA | Dividend yield |
|---|---|---|---|---|---|
| Wooree Bio | 11.8× | 0.2× | 0.0× | — | 2.3% |
| Samyang Foods | 17.5× | 5.6× | 3.1× | — | 0.4% |
| Orion | 10.5× | 1.1× | 1.2× | 5.3× | 3.1% |
| CJ Cheiljedang | — | 0.3× | 0.1× | — | 3.6% |
| Nongshim | 12.1× | 0.8× | 0.7× | — | 1.5% |
| Otoki | 16.9× | 0.6× | 0.3× | — | 2.9% |
| Hite Jinro | 23.3× | 1.0× | 0.4× | 6.4× | 4.5% |
| Similar companies (median) | 16.9× | 0.9× | 0.6× | 5.8× | 3.0% |
Calculated from end-of-day prices and filed financial statements. Not a recommendation. This is not financial advice.
Also known as: Wooree Bio / 우리바이오 / 082850 / KRX:082850
Source: KRX statistical information